Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York, NY, USA.
J Psychopharmacol. 2024 Mar;38(3):225-235. doi: 10.1177/02698811241232548. Epub 2024 Mar 4.
Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies.
A "bottom margin analysis" approach was taken to focus on negative responders to psychedelic use in a pool of naturalistic, observational prospective studies ( = 807). We define "negative response" by a clinically meaningful decline in a generic index of mental health, that is, one standard error from the mean decrease in psychological well-being 4 weeks post-psychedelic use (vs pre-use baseline). We then assessed whether a history of diagnosed mental illness can predict negative responses.
We find that 16% of the cohort falls into the "negative responder" subset. Parsing the sample by self-reported history of psychiatric diagnoses, results revealed a disproportionate prevalence of negative responses among those reporting a prior personality disorder diagnosis (31%). One multivariate regression model indicated a greater than four-fold elevated risk of adverse psychological responses to psychedelics in the personality disorder subsample ( = 1.425, < 0.05).
We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.
复苏的迷幻药研究在很大程度上支持了迷幻药疗法治疗各种精神疾病的安全性和有效性。随着迷幻药的使用和治疗越来越普及,了解相关风险变得越来越重要。似乎很少有长期对迷幻药治疗产生负面心理反应的病例;然而,由于研究存在偏见和样本量小,这些研究受到了限制。目前的分析方法是受到这样一个问题的启发,即迷幻药研究中是否有罕见但重要的不良影响被抽样不足。
采用“底部边缘分析”方法,关注自然主义、观察性前瞻性研究中对迷幻药使用产生负面反应的个体( = 807)。我们通过心理健康通用指数的临床显著下降来定义“负面反应”,即迷幻药使用后 4 周心理健康状况的平均下降幅度减去一个标准差(与使用前的基线相比)。然后,我们评估了既往精神疾病诊断是否可以预测负面反应。
我们发现,该队列中有 16%的人属于“负面反应者”亚组。通过自我报告的精神疾病诊断对样本进行细分,结果显示,报告先前存在人格障碍诊断的人群中负面反应的比例不成比例地高(31%)。一个多变量回归模型表明,人格障碍亚组对迷幻药产生不良心理反应的风险高出四倍以上( = 1.425, < 0.05)。
我们推断,人格障碍的存在可能代表着迷幻药使用的风险增加,并假设在该人群中增加心理支持和良好的治疗联盟可能更为重要。